Quidel Gains 80% Margin Potential With Litmus' Multi-Layered Film Testing
This article was originally published in The Gray Sheet
Executive Summary
Integration of Litmus Concepts' multi-layered film testing technology into Quidel's existing diagnostics portfolio will give Quidel an opportunity to achieve gross margins of over 80%, up from about 55% with its existing lateral flow immunoassay platform.
You may also be interested in...
Quidel LTF Format Pregnancy, Strep A Point-Of-Care Tests Expected By 2004
Quidel will expand its LTF layered thin film point-of-care test offerings to include pregnancy and Strep A by the end of 2003, the firm says
Deal Watch: AbbVie Teams With MedinCell On Long-Acting Injectables
Collaboration Edition: Including deals involving Evotec/Variant, Sanofi/IGM/Nurix, ABVC/OncoX and Harmony/Bioprojet, along with tech transfer agreements and deals in brief.